This research study aims to identify the national need of family medicine residency educators regarding point-of-care ultrasound (POCUS) education and resources. The study will collect data on the state of POCUS education and resources at medical universities across the country through an optional survey sent to faculty who are members of the Society of Teachers of Family Medicine. The questions in the survey focus on the respondee's level of POCUS training, use of POCUS in their day-to-day practice, and desire for different forms of POCUS content to integrate into their residency programs. The data will be collected and evaluated using Qualtrics.

The purpose of this study is to understand tobacco retailers' perceptions about the implications of retail-based policies for their business and assess feasibility of conducting interviews with tobacco retailers.

This study is examining Medicaid "unwinding", which refers to the process occurring nationwide of states resuming eligibility redeterminations for Medicaid enrollees after three years of continuous pandemic-related coverage protections. Over 15 million people are estimated to lose Medicaid coverage through this process, with nearly half still remaining eligible but facing administrative barriers to renew their coverage. This study focuses specifically on North Carolina's experiences with unwinding, utilizing a case study approach.The study aims to explore the factors shaping North Carolina's response, challenges encountered, and outcomes thus far. It also examines potential solutions to strengthen Medicaid policy for future redeterminations.

The purpose of this study is to identify specific barriers to preventing a late stage cancer diagnosis within communities identified in North Carolina as having a higher rate of advanced cancer diagnoses.

The study investigates the effects of conductive and sensorineural hearing loss on the ability to process speech and other complex sounds in the presence of competing noise. Psychoacoustic and speech perception approaches will be used to determine hearing abilities in listeners with hearing loss and to determine whether the derived data can be used to predict outcomes with hearing aids. The results will advance our basic understanding of the development of hearing in normal-hearing listeners and in hearing impaired patients.

The VITESSE phase 3 study is evaluating an investigational drug patch to learn how well it works in children with peanut allergy. The investigational drug patch is not yet approved by the United States Food and Drug Administration, European Medicines Agency, or any other regulatory agencies. To be eligible to this study, an individual must be: -4 to 7 years of age -Diagnosed with peanut allergy -Currently following a strict peanut free diet This is not a complete list of eligibility criteria. The study doctor will review the full entry criteria for this study with you. Eligible individuals will participate in this study for approximately 58 weeks (about 1 year). To learn more about the VITESSE study for children with peanut allergy, contact: Jenny Gartrell (jennifer_gartrell@med.unc.edu)

To assess undergraduate and graduate student's attitudes regarding opioid overdose and harm reduction tools at a large, public university.

The primary endpoints are to determine the recommended phase 2 dose (RP2D) of SNDX-5613 administered in combination with chemotherapy in patients with relapsed or refractory KMT2A-rearranged (KMT2A-R) acute lymphoblastic leukemia (ALL), and to estimate the minimal residual disease (MRD) negative remission rate of patients with R/R infant KMT2A-R ALL treated with SNDX-5613 in combination with chemotherapy. Secondary endpoints include characterizing the pharmacokinetics (PK) of SNDX-5613 administered with chemotherapy in patients with R/R infant KMT2A-R ALL, estimating the 18-month event-free survival (EFS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with chemotherapy, estimating 18-month overall survival (OS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with hemotherapy, and characterizing the tolerability of SNDX-5613 given as monotherapy in patients with R/R infant KMT2A-R ALL. The exploratory endpoint is to assess the biologic activity of SNDX-5613 administered with chemotherapy in patients with R/RKMT2A-R ALL.

The aim of this project is thus to explore people's judgments (e.g., fairness, efficiency) of different allocation procedures .

To better understand how people learn information and how they update (or integrate) that information as related information is learned later.